Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) Stock Competitors & Peer Comparison
See CUVL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CUVL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CUVL | $7.74 | -0.77% | 390.3M | N/A | N/A | N/A |
| RPRX | $61.31 | +1.21% | 27.2B | 11.68 | $5.25 | +1.50% |
| CORT | $122.25 | +2.71% | 13.1B | 345.86 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $68.62 | -3.42% | 6.1B | 490.14 | $0.14 | N/A |
| KNSA | $79.03 | +0.71% | 6B | 87.81 | $0.90 | N/A |
| PBH | $51.31 | +1.56% | 2.4B | 11.61 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| LTGO | $22.37 | +4.53% | 1.3B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
CUVL vs RPRX Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, RPRX has a market cap of 27.2B. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while RPRX trades at $61.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 11.68. In terms of profitability, CUVL's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CUVL is less volatile compared to RPRX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
CUVL vs CORT Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, CORT has a market cap of 13.1B. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while CORT trades at $122.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 345.86. In terms of profitability, CUVL's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, CUVL is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
CUVL vs WBA Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas WBA's P/E ratio is -1.64. In terms of profitability, CUVL's ROE is N/A, compared to WBA's ROE of -0.42%. Regarding short-term risk, CUVL is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
CUVL vs LQDA Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, LQDA has a market cap of 6.1B. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while LQDA trades at $68.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 490.14. In terms of profitability, CUVL's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, CUVL is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check LQDA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
CUVL vs KNSA Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while KNSA trades at $79.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 87.81. In terms of profitability, CUVL's ROE is N/A, compared to KNSA's ROE of +0.14%. Regarding short-term risk, CUVL is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check KNSA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
CUVL vs PBH Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while PBH trades at $51.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas PBH's P/E ratio is 11.61. In terms of profitability, CUVL's ROE is N/A, compared to PBH's ROE of +0.09%. Regarding short-term risk, CUVL is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
CUVL vs HROWL Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas HROWL's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, CUVL is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HROWL's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
CUVL vs LTGO Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, LTGO has a market cap of 1.3B. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while LTGO trades at $22.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas LTGO's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to LTGO's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check LTGO's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
CUVL vs HROWM Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas HROWM's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, CUVL is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HROWM's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
CUVL vs HELP Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, HELP has a market cap of 780.4M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while HELP trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas HELP's P/E ratio is -3.02. In terms of profitability, CUVL's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, CUVL is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
CUVL vs SVA Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas SVA's P/E ratio is -5.68. In terms of profitability, CUVL's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, CUVL is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SVA's competition here
High Tide Inc. (NASDAQ: HITI)
CUVL vs HITI Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, HITI has a market cap of 215.3M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while HITI trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas HITI's P/E ratio is 61.25. In terms of profitability, CUVL's ROE is N/A, compared to HITI's ROE of -0.43%. Regarding short-term risk, CUVL is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check HITI's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
CUVL vs CELG-RI Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, CELG-RI has a market cap of 208.4M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to CELG-RI's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CELG-RI's competition here
Atlantic International Corp. (NASDAQ: ATLN)
CUVL vs ATLN Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CUVL's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, CUVL is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
CUVL vs CTOR Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, CTOR has a market cap of 70.6M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while CTOR trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas CTOR's P/E ratio is -1.62. In terms of profitability, CUVL's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, CUVL is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CTOR's competition here
Stablecoin Development Corp. (AMEX: SDEV)
CUVL vs SDEV Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, SDEV has a market cap of 57M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while SDEV trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas SDEV's P/E ratio is -0.20. In terms of profitability, CUVL's ROE is N/A, compared to SDEV's ROE of +7.90%. Regarding short-term risk, CUVL is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SDEV's competition here
Rite Aid Corporation (NYSE: RAD)
CUVL vs RAD Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas RAD's P/E ratio is -0.05. In terms of profitability, CUVL's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, CUVL is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
CUVL vs GLTO Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CUVL's ROE is N/A, compared to GLTO's ROE of -0.83%. Regarding short-term risk, CUVL is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
CUVL vs NSRX Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, NSRX has a market cap of 34.5M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while NSRX trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas NSRX's P/E ratio is -5.56. In terms of profitability, CUVL's ROE is N/A, compared to NSRX's ROE of +0.00%. Regarding short-term risk, CUVL is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
CUVL vs SCYX Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, SCYX has a market cap of 32.1M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while SCYX trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.49. In terms of profitability, CUVL's ROE is N/A, compared to SCYX's ROE of -0.21%. Regarding short-term risk, CUVL is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SCYX's competition here
Cerenome, Inc. (NASDAQ: CNSY)
CUVL vs CNSY Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, CNSY has a market cap of 20.6M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while CNSY trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas CNSY's P/E ratio is -0.42. In terms of profitability, CUVL's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, CUVL is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRI)
CUVL vs BFRI Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, BFRI has a market cap of 18.9M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while BFRI trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -2.69. In terms of profitability, CUVL's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, CUVL is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BFRI's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
CUVL vs BFRIW Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, BFRIW has a market cap of 16.7M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, CUVL's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, CUVL is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
CUVL vs COSM Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, COSM has a market cap of 11.6M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while COSM trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas COSM's P/E ratio is -0.29. In terms of profitability, CUVL's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, CUVL is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check COSM's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
CUVL vs CJJD Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CUVL's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CUVL is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
CUVL vs SSY Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas SSY's P/E ratio is -2.86. In terms of profitability, CUVL's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, CUVL is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
CUVL vs POM Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, POM has a market cap of 6.5M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while POM trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas POM's P/E ratio is -0.19. In terms of profitability, CUVL's ROE is N/A, compared to POM's ROE of +0.16%. Regarding short-term risk, CUVL is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
CUVL vs BGMS Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, BGMS has a market cap of 4.9M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while BGMS trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas BGMS's P/E ratio is -0.25. In terms of profitability, CUVL's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, CUVL is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BGMS's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
CUVL vs PAVS Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, PAVS has a market cap of 4.3M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while PAVS trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas PAVS's P/E ratio is -0.06. In terms of profitability, CUVL's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, CUVL is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
CUVL vs MDVL Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CUVL's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CUVL is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
CUVL vs ATNFW Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, CUVL is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
CUVL vs BGMSP Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CUVL's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, CUVL is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
CUVL vs AZNH Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CUVL's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CUVL is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check AZNH's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
CUVL vs PRPH Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, PRPH has a market cap of 346.2K. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while PRPH trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas PRPH's P/E ratio is -0.01. In terms of profitability, CUVL's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, CUVL is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check PRPH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
CUVL vs LFLYW Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CUVL's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CUVL is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check LFLYW's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
CUVL vs ESRX Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CUVL's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CUVL is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check ESRX's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
CUVL vs CPD Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, CPD has a market cap of 0. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas CPD's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, CUVL is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check CPD's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
CUVL vs OREX Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, OREX has a market cap of 0. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas OREX's P/E ratio is -0.14. In terms of profitability, CUVL's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, CUVL is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check OREX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
CUVL vs IPXL Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CUVL's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CUVL is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check IPXL's competition here
POZEN Inc. (NASDAQ: POZN)
CUVL vs POZN Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, POZN has a market cap of 0. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas POZN's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, CUVL is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check POZN's competition here
Shire plc (NASDAQ: SHPG)
CUVL vs SHPG Comparison August 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 390.3M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CUVL is priced at $7.74 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of N/A, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CUVL's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CUVL is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SHPG's competition here